The impact of statin therapy in the COVID-19 patients with very high cardiovascular risk

• DOI: 10.5455/medscience.2022.10.222
• Publication Date: 2023-02-23T21:08:46Z
• Authors: Duygu Demirci; Deniz Demirci; Hande Cam; Kubra Onder; Figen gul; Gokhan Koker; Gulhan elik
• Keywords: Univariate analysis

Antithrombotic and anti-inflammatory impacts of statins have been studied in viral pneumonia. However, the clinical benefits not fully explored high-risk patients with coronavirus disease 2019 (COVID-19). Therefore, present study assessed effect statin use hospitalized COVID-19 very high cardiovascular risk. Consecutive admitted from June 1 to December 31, 2020, were analysed retrospectively. Propensity score-matched analysis was used for creating a 1:1 matched cohort. without compared demographic data, comorbidities, treatments, laboratory findings in-hospital outcomes. 707 (56±9.3 years old; 37% female) included. Among those, 24.6% (n=174) received therapy. A propensity-matched group 342 (171 receiving 171 statins) demarcated. The demonstrated that significantly reduced mortality within 30 days (primary end-point) univariate (OR=0.314, 95% CI: 0.195 0.507) multivariable-adjusted (OR=0.348, 0.187 0.648). risk, found be associated 30-days mortality.